C4 THERAPEUTICS INC (CCCC)
US12529R1077 - Common Stock
Overall CCCC gets a fundamental rating of 4 out of 10. We evaluated CCCC against 568 industry peers in the Biotechnology industry. CCCC has a great financial health rating, but its profitability evaluates not so good. CCCC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CCCC had negative earnings in the past year.
In the past year CCCC has reported a negative cash flow from operations.
In the past 5 years CCCC always reported negative net income.
In the past 5 years CCCC reported 4 times negative operating cash flow.
1.2 Ratios
CCCC's Return On Assets of -28.05% is fine compared to the rest of the industry. CCCC outperforms 70.97% of its industry peers.
CCCC has a better Return On Equity (-43.48%) than 70.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.05% | ||
| ROE | -43.48% | ||
| ROIC | N/A |
ROA(3y)-27.17%
ROA(5y)-26.81%
ROE(3y)-39.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CCCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CCCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CCCC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CCCC has more shares outstanding
CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -1.15, we must say that CCCC is in the distress zone and has some risk of bankruptcy.
CCCC has a Altman-Z score (-1.15) which is in line with its industry peers.
CCCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.15 |
ROIC/WACCN/A
WACC11.95%
2.3 Liquidity
A Current Ratio of 6.31 indicates that CCCC has no problem at all paying its short term obligations.
CCCC's Current ratio of 6.31 is fine compared to the rest of the industry. CCCC outperforms 63.19% of its industry peers.
A Quick Ratio of 6.31 indicates that CCCC has no problem at all paying its short term obligations.
CCCC has a Quick ratio of 6.31. This is in the better half of the industry: CCCC outperforms 63.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.31 | ||
| Quick Ratio | 6.31 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 37.00% over the past year.
Looking at the last year, CCCC shows a very strong growth in Revenue. The Revenue has grown by 65.51%.
The Revenue has been growing slightly by 1.40% on average over the past years.
EPS 1Y (TTM)37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
Revenue 1Y (TTM)65.51%
Revenue growth 3Y-14.49%
Revenue growth 5Y1.4%
Sales Q2Q%38.75%
3.2 Future
The Earnings Per Share is expected to grow by 11.85% on average over the next years. This is quite good.
The Revenue is expected to grow by 48.64% on average over the next years. This is a very strong growth
EPS Next Y42.03%
EPS Next 2Y15.92%
EPS Next 3Y11.3%
EPS Next 5Y11.85%
Revenue Next Year67.37%
Revenue Next 2Y-13.57%
Revenue Next 3Y-6.86%
Revenue Next 5Y48.64%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CCCC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CCCC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.92%
EPS Next 3Y11.3%
5. Dividend
5.1 Amount
No dividends for CCCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
C4 THERAPEUTICS INC
NASDAQ:CCCC (12/18/2024, 5:55:08 PM)
After market: 3.7 +0.05 (+1.37%)3.65
-0.4 (-9.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap257.65M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.05% | ||
| ROE | -43.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.31 | ||
| Quick Ratio | 6.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)37%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y42.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)65.51%
Revenue growth 3Y-14.49%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y